Antonio Bertoletti

Professor

Duke-NUS Medical School

Singapore

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Antonio Bertoletti is a Professor at Duke-NUS Medical School, Singapore. His research focuses on the immune response in chronic hepatitis B virus (HBV) infection, the dynamics of T-cell responses in various contexts, and the engineering of T cells for targeted immunotherapy in liver cancer. Recent publications reflect his interest in the interplay between immune mechanisms and therapeutic strategies in viral infections and cancer.

Articles (18)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (6)

Andrea Pavesi

National University of Singapore (NUS)

SINGAPORE

View details

Georg Lauer

Associate Professor of Medicine

Harvard Medical School

UNITED STATES

View details

Carolina Boni

University of Parma

ITALY

View details

Adam J. Gehring

University of Toronto

CANADA

View details

Anthony Tanoto TAN

Assistant Professor

Duke-NUS Medical School

SINGAPORE

View details

Kyong-Mi Chang

Professor of Medicine & Associate Chief of Staff for R&D

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Antonio Bertoletti

Research Interests

Explore related searches

Contact this professor

About

Articles (18)

In vitro integration of a functional vasculature to model endothelial regulation of chemotherapy and T-cell immunotherapy in liver cancer

Dynamics of virus-specific CD8+ T cells in the human nasal cavity

Reply to correspondence on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”

A rapid method to assess the in vivo multi-functionality of adoptively transferred engineered TCR T cells

The immune response in chronic HBV infection

SARS-CoV-2 immunity

Beyond exhaustion: the unique characteristics of CD8+ T cell dysfunction in chronic HBV infection

Engineering HBV-specific T cells for the treatment of HBV-related HCC and HBV infection: Past, Present, and Future. <i>Editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”</i>

Comment on ‘End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB’

Quest for immunological biomarkers in the management of CHB patients

Protocol to detect antigen-specific nasal-resident T cells in humans

Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood

Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines

HBV antigens quantity: duration and effect on functional cure

SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and CD4+ T cells of broad specificity

SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic

Act Early and at the Right Location: SARS-CoV-2 T Cell Kinetics and Tissue Localization

The challenges of adopting immunological biomarkers in the management of chronic HBV infection

Collaborators (6)

Andrea Pavesi

Georg Lauer

Carolina Boni

Adam J. Gehring

Anthony Tanoto TAN

Kyong-Mi Chang

Make your next move.